{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:02:30Z","timestamp":1777874550376,"version":"3.51.4"},"reference-count":72,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with urothelial (UC) or ovarian\/fallopian tube cancer (OC\/FTC) with\n                      <jats:italic toggle=\"yes\">ERBB2\/3<\/jats:italic>\n                      alterations treated with pertuzumab plus trastuzumab (P + T) are reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Eligible patients had advanced cancer, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with\n                      <jats:italic toggle=\"yes\">ERBB2\/3<\/jats:italic>\n                      alterations, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. Simon's two-stage design is based on a null DC rate of 15% versus 35% (power = 0.85; \u03b1 = .10). Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Patients with UC (n = 28) or OC\/FTC (n = 25) with\n                      <jats:italic toggle=\"yes\">ERBB2\/3<\/jats:italic>\n                      alterations were enrolled from March 2017 to June 2023. In the UC cohort, the DC and OR rates were 37% (90% CI, 24 to 100) and 25% (95% CI, 11 to 45), respectively. The null hypothesis of 15% DC rate was rejected (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .005). In the OC\/FTC cancer cohort, the DC and OR rates were 23% (90% CI, 9 to 100) and 8% (95% CI, 1 to 26), respectively. The null hypothesis of 15% DC rate was not rejected (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .35). Six patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      The combination of P + T met prespecified criteria to declare a signal of activity in patients with UC with\n                      <jats:italic toggle=\"yes\">ERBB2\/3<\/jats:italic>\n                      alterations, but not in patients with OC\/FTC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-01250","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:59:11Z","timestamp":1777579151000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Pertuzumab and Trastuzumab in Patients With\n                    <i>ERBB2\/3<\/i>\n                    -Altered Urothelial or Ovary\/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study"],"prefix":"10.1200","volume":"10","author":[{"given":"John K.","family":"Chan","sequence":"first","affiliation":[{"name":"Sutter Cancer Research Consortium, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":true,"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Pisick","sequence":"additional","affiliation":[{"name":"City of Hope Chicago, Zion, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Ghatalia","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1018-519X","authenticated-orcid":true,"given":"Andrew","family":"Gregory","sequence":"additional","affiliation":[{"name":"Advocate Aurora Healthcare, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mollie","family":"deShazo","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-7743","authenticated-orcid":true,"given":"Kathryn F.","family":"Mileham","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina C.","family":"Murphy","sequence":"additional","affiliation":[{"name":"University of Florida Health, Gainesville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-4725","authenticated-orcid":true,"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7851-5165","authenticated-orcid":true,"given":"Elie G.","family":"Dib","sequence":"additional","affiliation":[{"name":"Michigan Cancer Research Consortium, Ypsilanti, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Kohler","sequence":"additional","affiliation":[{"name":"Cancer Research Consortium of West Michigan, Cowell Family Cancer Center, Munson Medical Center, Traverse City, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-1652","authenticated-orcid":true,"given":"Justin T.","family":"Moyers","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-6742","authenticated-orcid":true,"given":"Pam K.","family":"Mangat","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9484","authenticated-orcid":true,"given":"Dominique C.","family":"Hinshaw","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":true,"given":"Abigail","family":"Gregory","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":true,"given":"Gina N.","family":"Grantham","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":true,"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02842-1"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0845"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1565872"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0430"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00519"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02331"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00762"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4091"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503704"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00380-2"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00064-0"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00884"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102351"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01056-x"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217146"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246174"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1791"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24337"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.3047"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02636"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0633"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3020"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25475"},{"key":"e_1_3_11_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.04.012"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.11.021"},{"key":"e_1_3_11_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.02.002"},{"key":"e_1_3_11_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021457"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS587"},{"key":"e_1_3_11_36_2","article-title":"Rationale and design of the targeted agent and profiling utilization registry study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/po.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"e_1_3_11_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"e_1_3_11_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_11_40_2","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR Study","author":"Yang ES","unstructured":"Yang ES, Halabi S, Rothe M, et al: Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR Study. JCO Precis Oncol 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_41_2","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR Study","author":"Gupta R","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR Study. JCO Precis Oncol 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_42_2","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study","author":"Klute KA","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, et al: Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study. JCO Precis Oncol 10.1200\/PO.22.00191","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00702"},{"key":"e_1_3_11_44_2","article-title":"Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00240","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_45_2","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study","author":"Rohatgi N","unstructured":"Rohatgi N, Rothe M, Mangat PK, et al: Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study. JCO Precis Oncol 10.1200\/PO.23.00279","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_46_2","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study","author":"Calfa CJ","unstructured":"Calfa CJ, Rothe M, Mangat PK, et al: Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00513","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_47_2","doi-asserted-by":"publisher","unstructured":"Sahai V Rothe M Mangat PK et al: Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) Study. JCO Precis Oncol 10.1200\/PO.23.00527","DOI":"10.1200\/PO.23.00527"},{"key":"e_1_3_11_48_2","doi-asserted-by":"publisher","unstructured":"Cannon TL Rothe M Mangat PK et al: Pertuzumab plus trastuzumab in patients with biliary tract cancer with ERBB2\/3 alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/JCO.23.02078","DOI":"10.1200\/JCO.23.02078"},{"key":"e_1_3_11_49_2","article-title":"Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study","author":"Srkalovic G","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al: Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.24.00026","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104545"},{"key":"e_1_3_11_51_2","article-title":"Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry study","author":"Schuetze S","unstructured":"Schuetze S, Rothe M, Mangat PK, et al: Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.24.00219","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_52_2","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR Study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR Study. JCO Precis Oncol 10.1200\/PO.22.00609","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_53_2","article-title":"Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry study","author":"Ganti AK","unstructured":"Ganti AK, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00041","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_54_2","article-title":"Palbociclib in patients with Non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Mangat PK, Garrett-Mayer E, et al: Palbociclib in patients with Non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.20.00037","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_55_2","article-title":"Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study","author":"Meric-Bernstam F","unstructured":"Meric-Bernstam F, Rothe M, Mangat PK, et al: Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00385","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_11_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_11_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.3468"},{"key":"e_1_3_11_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0467"},{"key":"e_1_3_11_60_2","article-title":"OncoKB: A precision oncology knowledge base","author":"Chakravarty D","unstructured":"Chakravarty D, Gao J, Phillips S, et al: OncoKB: A precision oncology knowledge base. JCO Precis Oncol 10.1200\/PO.17.00011","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.09.010"},{"key":"e_1_3_11_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-20-0094"},{"key":"e_1_3_11_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.3541"},{"key":"e_1_3_11_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.104"},{"key":"e_1_3_11_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02626"},{"key":"e_1_3_11_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70052"},{"key":"e_1_3_11_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0898"},{"key":"e_1_3_11_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"e_1_3_11_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3682"},{"key":"e_1_3_11_70_2","first-page":"1403","article-title":"HER2 in metastatic colorectal cancer: Pathology, somatic alterations, and perspectives for novel therapeutic schemes","volume":"12","author":"Ivanova M","year":"2022","unstructured":"Ivanova M, Venetis K, Guerini-Rocco E, et al: HER2 in metastatic colorectal cancer: Pathology, somatic alterations, and perspectives for novel therapeutic schemes. Life (Basel) 12:1403, 2022","journal-title":"Life (Basel)"},{"key":"e_1_3_11_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2533"},{"key":"e_1_3_11_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03966-7"},{"key":"e_1_3_11_73_2","article-title":"Fidelity of next-generation sequencing to predict human epidermal growth factor 2 overexpression across solid tumors","author":"Tran M","unstructured":"Tran M, Fausel CA, Bray S, et al: Fidelity of next-generation sequencing to predict human epidermal growth factor 2 overexpression across solid tumors. JCO Precis Oncol 10.1200\/PO-24-00935","journal-title":"JCO Precis Oncol"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-01250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:59:18Z","timestamp":1777579158000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-01250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1200\/PO-25-01250"],"URL":"https:\/\/doi.org\/10.1200\/po-25-01250","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2501250"}}